secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0000950170-23-027939
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Therapeutics stockholders approve officer liability amendment, elect directors
--------------------------------------------------------------------------------

- Amendment to certificate of incorporation to limit officer liability as per Delaware law approved (42.5M for, 567k against).
- Andrew Schiff, M.D. and Chandra P. Leo elected as Class II directors for three-year term ending 2026.
- Deloitte & Touche ratified as independent auditor for FY2023.
- Broker non-votes of 2,225,742 on director and amendment proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023027939/0000950170-23-027939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023027939/glue-20230614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer